The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

The clinical results of the NIAGARA study of Imfinzi (durvalumab) – which were previewed by AZ in June – are pretty much a home run, showing a clear benefit in event-free survival (PFS), as ...

Imfinzi (durvalumab) has been cleared by the US regulator for the treatment of adult patients with locally advanced or metastatic BTC in combination with gemcitabine/cisplatin chemotherapy ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab) for approval in the European Union (EU) as a single agent for ...

The Business Research Company's Imfinzi (durvalumab) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to ...

AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer treatments, Tagrisso (osimertinib) and ...

on Wednesday provided an update on its Phase 1b/2 DURIPANC clinical trial evaluating the combination of Ampligen or rintatolimod and Imfinzi or durvalumab in treating late-stage pancreatic cancer.

AstraZeneca's Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...